New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck,

New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and
Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca,
                             and GlaxoSmithKline

PR Newswire

NEW YORK, September 16, 2013

NEW YORK, September 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), Allergan Inc. (NYSE: AGN), Mylan, Inc. (NASDAQ: MYL),
AstraZeneca PLC (NYSE: AZN), and GlaxoSmithKline plc (NYSE: GSK). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On September 9, 2013, Merck & Co. Inc. (Merck) announced that its New Drug
Application (NDA) for the investigational fertility treatment, corifollitropin
alfa, has received acceptance for standard review by the US Food and Drug
Administration (FDA). Further, Merck stated that it is seeking FDA approval of
corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women
participating in assisted reproductive technology, which if approved, will
mark corifollitropin alfa as the first sustained follicular stimulant for use
in a fertility treatment regimen. Barbara Stegmann, M.D., Reproductive
Endocrinology and Infertility Specialist, and Principal Scientist and Clinical
Lead Fertility, Merck, said, "The filing of corifollitropin alfa is an example
of Merck's commitment to patients and scientific innovation." The Full
Research Report on Merck & Co. Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-11/MRK]

--

Allergan Inc. Research Report

On September 11, 2013, Allergan Inc. (Allergan) announced that the US Food and
drug Administration (FDA) has approved the marketing of its BOTOX Cosmetic
(onabotulinumtoxinA), for an additional indication to temporarily treat
moderate to severe lateral canthal lines, commonly known as "crow's feet"
lines. Scott W. Whitcup M.D., Executive Vice President, Research and
Development, Chief Scientific Officer at Allergan, said, "We are pleased that
the FDA has approved a new indication for BOTOX Cosmetic to temporarily
improve the appearance of crow's feet lines. With this approval, BOTOX
Cosmetic is now the only pharmaceutical approved to treat both crow's feet
lines and frown lines between brows. This approval will enhance our ability to
work with and train aesthetic physicians on the science of administering BOTOX
Cosmetic to yield the best possible outcomes for patients." The Full Research
Report on Allergan Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-11/AGN]

--

Mylan, Inc. Research Report

On September 3, 2013, Mylan Inc. (Mylan) announced that India's Foreign
Investment Promotion Board (FIPB) and Cabinet Committee on Economic Affairs
(CCEA) have approved its proposed acquisition of the Agila injectables
businesses from Strides Arcolab Limited. Mylan's CEO, Heather Bresch
commented, "We are very pleased to have received all outstanding Indian
pre-merger regulatory approvals for the Agila transaction, especially
considering the increased government regulation and oversight with respect to
foreign investment in India. We look forward to completing the acquisition in
the coming months, which we believe will establish Mylan as a global
injectables leader, with a significantly expanded and strengthened injectables
portfolio, pipeline, platform and capabilities." The Company expects the
transaction to close in Q4 2013, subject to remaining regulatory approvals and
certain closing conditions. The Full Research Report on Mylan, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-11/MYL]

--

AstraZeneca PLC Research Report

On September 11, 2013, AstraZeneca PLC (AstraZeneca) announced that it has
entered into a worldwide licensing agreement with Merck Co. Inc. (Merck) for
the latter's oral small molecule inhibitor of WEE1 kinase (MK-1775). The
Company informed that MK-1775 is undergoing evaluation in Phase IIa clinical
studies in combination with standard of care therapies for the treatment of
patients with certain types of ovarian cancer. Under the terms of agreement,
AstraZeneca will pay $50 million upfront fee and will be responsible for all
future clinical development, manufacturing and marketing, while Merck will be
eligible to receive future payments tied to development and regulatory
milestones plus sales-related payments and tiered royalties. "MK-1775 is a
strong addition to AstraZeneca's growing oncology pipeline, which already
includes a number of inhibitors of the DNA damage response," said Susan
Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. "The
compound has demonstrated encouraging clinical efficacy data and we intend to
study it in a range of cancer types where there is a high unmet medical need."
The Full Research Report on AstraZeneca PLC - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-11/AZN]

--

GlaxoSmithKline plc Research Report 

On September 9, 2013, GlaxoSmithKline plc (GSK) announced that it has signed
an agreement to sell its nutritional drink brands, Lucozade and Ribena, to
Suntory Beverage & Food Ltd. (SBF) against a consideration of c.£1.4 billion
in cash. The Company informed that under the terms of the agreement, SBF will
acquire global rights to the brands and GSK's Coleford manufacturing site,
located in the Forest of Dean in the UK, however, in Nigeria, GSK will
continue to manufacture and distribute Lucozade and Ribena under licence from
SBF. David Redfern, Chief Strategy Officer, GSK, said, "Lucozade and Ribena
are iconic brands that have made a huge contribution to GSK over the years,
but now is the right time to sell them as we increase the focus of our
Consumer Healthcare business and execute the delivery of our late stage
pipeline of pharmaceuticals and vaccines." The Company expects the transaction
to be completed by the end of 2013, subject to regulatory approvals. The Full
Research Report on GlaxoSmithKline plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-11/GSK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders ; +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.